← All trials
NCT03208556
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2017
- Primary completion
- Jun 1, 2019
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peking UniversityLead sponsor
- Chinese Academy of Medical SciencesStudy director
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Marino Biotechnology Co., Ltd.Study director
- Marino Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.